Dermatophagoides pteronyssinus allergen proteins (Der p allergens)

Dermatophagoides pteronyssinus allergen proteins are a diverse group of antigens produced by the European house dust mite that serve as major triggers for respiratory and cutaneous allergic diseases (WHO/IUIS Allergen Nomenclature). The most prominent members, such as Der p 1 and Der p 2, possess biochemical activities—including proteolytic degradation of tight junctions and lipid-binding mimicry of MD-2—that facilitate their allergenicity by promoting Th2-weighted immune responses (PMID: 30103934). These proteins are the primary targets of allergen-specific immunotherapy (AIT), where they are administered in controlled doses to induce immunological desensitization. This therapeutic approach aims to shift the patient's immune profile from an IgE-mediated hypersensitivity toward a state of tolerance characterized by increased regulatory T cells and IgG4 blocking antibodies (PMID: 27502294). Consequently, these allergen proteins are essential for both the diagnosis of house dust mite allergy and the formulation of disease-modifying treatments like sublingual and subcutaneous immunotherapy (FDA Odactra Label).

Other names

House dust mite allergensHDM allergensDer pEuropean house dust mite allergens

Allergen-specific immunotherapy (AIT) involves the repeated administration of specific allergens to induce immunological tolerance. This process shifts the immune response from a Th2-dominated profile to a Th1/Treg-mediated response, increasing the production of blocking antibodies such as IgG4 and reducing the activation of mast cells and basophils (PMID: 27502294).